Miconazole
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
Miconazole: From Antifungal Use to Acne
One-Sentence Summary
Miconazole is a long-established azole antifungal, marketed in the US mainly as topical creams, sprays and powders. The TxGNN model predicts it may be effective for acne, but the support is thin: 1 clinical trial (a suspended combination-product study that does not isolate miconazole) and 4 publications, only one of which examines an acne-related condition treated with an azole.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Acne |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L4 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the record. Miconazole belongs to the imidazole class of antifungals, which inhibit fungal ergosterol synthesis (CYP51). Its efficacy against fungal skin infections is long established, and mechanistically it may be applicable to acne-related skin conditions.
The link to acne is plausible but indirect, for three reasons:
- Miconazole has shown in vitro activity against Propionibacterium acnes (Cutibacterium acnes), the bacterium implicated in acne vulgaris, and against some other Gram-positive bacteria. Azole antifungals as a class show similar activity (PMID 20045949).
- A review describes anti-inflammatory effects of miconazole on skin (PMID 18627330).
- Some acne-like eruptions are actually Malassezia (Pityrosporum) folliculitis, which responds to azoles. This subset is often misdiagnosed as acne vulgaris (PMID 8593718). Benefit here may not carry over to true acne vulgaris.
The very high TxGNN score is a model output, not clinical evidence. No dose, formulation or efficacy data for acne currently exist.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01244256 | Phase 2/3 | Suspended | 80 | Tests a fixed combination cream (beclomethasone + gentamicin + an antifungal, likely clotrimazole) in contaminated dermatosis with bilateral symmetrical lesions. No results posted. Miconazole’s own contribution cannot be separated, and the acne relevance is unconfirmed (relevance grade C). |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15536660 | 2004 | Clinical study (split-face) | Skin Res Technol | Split-face clinical and bioinstrumental assessment in mild catamenial acne. The available abstract excerpt does not describe miconazole-specific results. |
| 8593718 | 1995 | Clinical study | Clin Exp Dermatol | 62 patients with Pityrosporum folliculitis, an acne mimic often misdiagnosed as acne vulgaris. Diagnosis was confirmed by histology and microscopy, and therapeutic trials were included. |
| 18627330 | 2008 | Review | Expert Opin Pharmacother | Overview of the multifaceted effects of miconazole nitrate on skin disorders. |
| 20045949 | 2010 | In vitro study | Biol Pharm Bull | Azole antifungals were tested against P. acnes isolates from acne vulgaris patients, motivated by rising antibiotic resistance. |
US Market Information
The record lists 20 licenses in total. The main ones are shown below.
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| M005 | MICONAZOLE Nitrate 2% | Cream | Akron Pharma Inc. |
| ANDA076773 | Miconazole 3 | Cream | TARGET Corporation |
| M005 | Miconazole Nitrate | Aerosol, spray | American Sales Company |
| M005 | Anti-Fungal Powder | Powder | CVS Pharmacy |
| ANDA074760 | good sense miconazole 7 | Cream | L. Perrigo Company |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score and indirect evidence (in vitro anti-C. acnes activity and azole-responsive Malassezia folliculitis). The only registered trial is a suspended combination-product study that cannot support a miconazole-specific claim. This is best treated as a research question rather than a development candidate.
To proceed, the following is needed:
- Package insert warnings and contraindications, and detailed MOA data
- Clear separation of acne vulgaris from Malassezia folliculitis in any future study
- A controlled clinical study of miconazole in acne vulgaris, with defined formulation, dose and endpoints
- Confirmation that the miconazole component itself, not the combination partners, drives any observed effect
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.